Skip to main content
Premium Trial:

Request an Annual Quote

Leaders Chosen for Biomarker Firm Eclipse Diagnostics

Premium

Eclipse Diagnostics, the newly formed subsidiary of Large Scale Biology, has gotten its management team in place. Comprised entirely of members of the parent company, which will continue to focus on biomolecule production, the group will be responsible for commercializing the biomarker amplification filter technology — known as BAMF — that serves as the foundation of the new company.

John Rakitan, senior vice president and general manager for Eclipse, says the technology is designed to screen thousands of potential markers to find a clearer diagnostic signature than any one marker might offer. “This concept is not new,” he says, but the company is clearly committed to it: “This is going to be a method that we think will actually revolutionize medicine.”

Kevin Ryan, president and CEO of Large Scale Biology, is the new president of Eclipse. He’s joined by Rakitan, Gary Wolfe as CSO, Guy della Cioppa as senior veep of business development, and Ronald Artale in the position of CFO. John Chute, a Duke Medical Center faculty member who used to work for LSBC, has signed on as Eclipse’s first scientific advisor.

The team will start with a focus on ovarian cancer, which they’ve already been pursuing thanks to a collaboration with Lance Liotta and Emanuel Petricoin at the NCI/FDA Clinical Proteomics Program. In the future, Rakitan says, Eclipse will likely look into other cancers, such as lung, breast, pancreatic, and possibly more ovarian datasets. If the BAMF technology works as well as the Eclipse team is betting it will, Rakitan says, “It’s going to provide better patient outcome and dramatically reduce the cost of healthcare.”

— Meredith Salisbury

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.